IRINOTECAN INTAS irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

irinotecan hydrochloride trihydrate, Quantity: 300 mg

Commercializzato da:

Accord Healthcare Pty Ltd

Forma farmaceutica:

Injection, concentrated

Composizione:

Excipient Ingredients: hydrochloric acid; sodium hydroxide; lactic acid; water for injections; sorbitol

Via di somministrazione:

Intravenous Infusion

Confezione:

1

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Dettagli prodotto:

Visual Identification: A pale yellow clear solution; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2020-03-05